RVPH 8-K: Company Furnishes Q2 2025 Financial Results (Exhibit 99.1)

Rhea-AI Filing Summary

Reviva Pharmaceuticals Holdings, Inc. furnished a Current Report on Form 8-K stating it issued a press release on August 14, 2025 that discloses financial information and operating metrics for the fiscal quarter ended June 30, 2025 and discusses business outlook. The filing indicates the press release is attached as Exhibit 99.1 and is incorporated by reference into the report. The company also states the information is being furnished to the SEC and expressly is not being "filed" for purposes of Exchange Act Section 18, limiting the legal liabilities associated with formal filed disclosures.

Positive

• Press release issued disclosing financial information and operating metrics for the quarter ended June 30, 2025
• Exhibit 99.1 furnished with the 8-K, signaling timely disclosure of quarter results
• Explicit statement that information is furnished to the SEC, aligning with disclosure procedures

Negative

• The 8-K text does not include the underlying financial figures or operating metrics (those are in Exhibit 99.1)
• Information is furnished, not filed, which limits statutory Section 18 liability and may affect incorporation into later filings

Insights

Financial Analyst

TL;DR: Company furnished a results press release for the quarter ended June 30, 2025; the 8-K itself contains no numeric financial data.

The filing notifies investors that a press release containing quarter-end financials and operating metrics was issued and is attached as Exhibit 99.1. Because the registrant states the information is "furnished" rather than "filed," the 8-K limits statutory liability for the disclosed content. From an analytical standpoint, this is a routine disclosure mechanism to distribute quarterly results outside of a formal 10-Q amendment or proxy filing. Materiality depends entirely on the content of Exhibit 99.1, which is not included in this text. The 8-K confirms timeliness of disclosure but does not by itself allow assessment of revenue, profit, or cash metrics.

Corporate Governance Expert

TL;DR: The company followed Regulation FD and SEC furnishing practice; legal exposure is limited by furnishing language.

This Form 8-K documents a Regulation FD-style disclosure: a press release was furnished and incorporated as an exhibit. The filing explicitly states the exhibit is furnished and not filed, which is a standard governance/legal approach to control incorporation and liability under the federal securities laws. The document also references Regulation FD (Items 2.02 and 7.01), indicating the company is meeting public disclosure obligations. No governance or management changes, related-party transactions, or remediation actions are described in this filing.

false 0001742927 0001742927 2025-08-14 2025-08-14 0001742927 rvph:CommonStockParValue00001PerShareCustomMember 2025-08-14 2025-08-14 0001742927 rvph:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2025-08-14 2025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): August 14, 2025

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38634		85-4306526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

10080 N Wolfe Road, Suite SW3-200, Cupertino, CA		95014
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (408) 501-8881

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RVPH		Nasdaq Capital Market
Warrants to purchase one share of Common Stock		RVPHW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on August 14, 2025, disclosing financial information and operating metrics for its fiscal quarter ended June 30, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following Exhibit 99.1 is furnished with this report:

Exhibit No.		Description
99.1		Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated August 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Dated: August 14, 2025	By:	/s/ Narayan Prabhu
	Name: Title:	Narayan Prabhu Chief Financial Officer

FAQ

What did Reviva Pharmaceuticals (RVPH) disclose in this Form 8-K?

The company disclosed it issued a press release on August 14, 2025 containing financial information and operating metrics for the fiscal quarter ended June 30, 2025, and attached that press release as Exhibit 99.1.

Does this 8-K include the actual financial numbers for Q2 2025?

No. The 8-K states a press release with financial information was furnished as Exhibit 99.1; the numeric financials are not contained in the 8-K text provided here.

Is the information in this Form 8-K considered "filed" with the SEC?

No. The filing explicitly states the information and Exhibit 99.1 are being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Which Items of the Form 8-K are referenced?

The filing references Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) and indicates Exhibit 99.1 is incorporated by reference into those items.

Where can investors find the detailed financial metrics mentioned?

The detailed financial metrics and operating information are contained in the press release attached as Exhibit 99.1, which should be available on the company’s SEC filings page or investor relations site.